ENeura Therapeutics, a neuromod developer, today filed an SEC Form D to confirm the sale of nearly $6 million in a debt offering. The new notice’s first sale was made last week. The Baltimore-based company does not intend for the offering to last for more than one year. ENeura’s offering total was set at nearly […]
Neuromod developers ENeura said yesterday it closed a $17 million Series D round to help support its sTMS transcranial magnetic stimulation system designed for the acute treatment and prevention of migraines. Funding in the round was led by Camden Partners Nexus, the Baltimore-based company said. Proceeds raised in the round will help support continued commercial […]
Maryland-based migraine devices maker eNeura is closing in on a $6.6 million funding round, with $5.8 million raised so far.
eNeura has won FDA clearance since the making of this video.
eNeura’s SpringTMS system is the 1st of its kind to use transcranial magnetic stimulation to depolarize neurons on the brain, a process that doctors believe may interrupt migraine activity. Designed for home use, patients place the device against the back of the head, where a magnetic pulse targets the occipital lobe.
Maryland medical device maker eNeura today touted FDA clearance for its SpringTMS system, a mobile magnetic stimulator that can help relieve pain associated with migraines that are preceded by an ‘aura.’
eNeura Therapeutics added to the $2.2 million it raised earlier this year with another $1.6 million deposit, part of a hoped-for $2 million funding round, according to a regulatory filing.
Sunnyvale, Calif.-based eNeura makes a transcranial magnetic stimulation device designed to treat migraine headaches.
eNeura Therapeutics, hard on the heels of an FDA nod for its migraine technology, brought in $2.2 million from an equity offering.
The medtech maker list a lone unnamed investor in late Dec., according to a regulatory filing.
Medtech maker eNeura Therapeutics won FDA clearance to market its 1st-of-its-kind Cerena transcranial magnetic stimulator, landing regulatory approval through the agency’s less-stringent de novo premarket review pathway.
The Cerena TMS is now the 1st available device to relieve migraine headache pain caused by auras, eNeura said.